G Steven Bova – PELICAN Personalized Cancer Medicine


Kallio HML, Hieta R, Latonen L, Brofeldt A, Annala M, Kivinummi K, Tammela TL, Nykter M, Isaacs WB, Lilja HG, Bova GS, Visakorpi T
Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.
Br J Cancer ;119(3)347-356, 2018
PMID

Sainio M, Visakorpi T, Tolonen T, Ilvesaro J, Bova GS
Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Pathol Res Pract ;214(6)848-856, 2018
PMID

Högnäs G, Kivinummi K, Kallio HML, Hieta R, Ruusuvuori P, Koskenalho A, Kesseli J, Tammela TLJ, Riikonen J, Ilvesaro J, Kares S, Hirvikoski PP, Laurila M, Mirtti T, Nykter M, Kujala PM, Visakorpi T, Tolonen T, Bova GS
Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues.
Am J Surg Pathol ;42(1)103-115, 2018
PMID

Jorma Isola – Cancer biology

Turkki R, Byckhov D, Lundin M, Isola J, Nordling S, Kovanen PE, Verrill C, von Smitten K, Joensuu H, Lundin J, Linder N
Breast cancer outcome prediction with tumour tissue images and machine learning.
Breast Cancer Res Treat ;177(1)41-52, 2019
PMID

Le Joncour V, Martins A, Puhka M, Isola J, Salmikangas M, Laakkonen P, Joensuu H, Barok M
A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast And Gastric Cancers Resistant to Trastuzumab Emtansine.
Mol Cancer Ther ;2019
PMID

Isola JVV, Velasco Acosta DA, Bespalhok Jacometo C, Rincón JAA, Silveira PAS, Corrêa MN, Schneider A
Intrafollicular paraoxonase 1 activity and the steroidogenic potential of the first post-partum dominant follicle in dairy cows.
Reprod Domest Anim ;54(6)924-927, 2019
PMID


Luhtala S, Staff S, Kallioniemi A, Tanner M, Isola J
Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
BMC Cancer ;18(1)1045, 2018
PMID

Luhtala S, Haapaniemi T, Staff S, Isola J
Fluoro-Chromogenic Labelling for Detection of MCM2 to Assess Proliferation Activity in HER2-amplified Breast Carcinomas.
Appl Immunohistochem Mol Morphol ;2018
PMID

Barok M, Puhka M, Vereb G, Szollosi J, Isola J, Joensuu H
Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation.
BMC Cancer ;18(1)504, 2018
PMID

Schaffer-Smith D, Swenson JJ, Reiter ME, Isola JE
Quantifying shorebird habitat in managed wetlands by modeling shallow water depth dynamics.
Ecol Appl ;28(6)1534-1545, 2018
PMID

Koivusalo L, Kaipia A, Kujala P, Isola J, Tolonen TT
Digital image analysis of the tissue surface areas of site-designated and bilaterally pooled prostate biopsies.
Histol Histopathol ;33(4)399-405, 2018
PMID

Luhtala S, Staff S, Barok M, Tanner M, Isola J
Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer.
Appl Immunohistochem Mol Morphol ;26(3)212-219, 2018
PMID

Helin H, Tolonen T, Ylinen O, Tolonen P, Näpänkangas J, Isola J
Optimized JPEG 2000 Compression for Efficient Storage of Histopathological Whole-Slide Images.
J Pathol Inform ;2018
PMID

Anne KallioniemiCancer Genomics

Nurmi A, Muranen TA, Pelttari LM, Kiiski JI, Heikkinen T, Lehto S, Kallioniemi A, Schleutker J, Bützow R, Blomqvist C, Aittomäki K, Nevanlinna H
Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
Int J Cancer ;2019
PMID

Vuorinen EM, Rajala NK, Ihalainen TO, Kallioniemi A
Correction to: Depletion of nuclear import protein karyopherin alpha 7 (KPNA7) induces mitotic defects and deformation of nuclei in cancer cells.
BMC Cancer ;19(1)57, 2019
PMID


Luhtala S, Staff S, Kallioniemi A, Tanner M, Isola J
Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
BMC Cancer ;18(1)1045, 2018
PMID

Abu Khamidakh AE, Rodriguez-Martinez A, Kaarniranta K, Kallioniemi A, Skottman H, Hyttinen J, Juuti-Uusitalo K
Wound healing of human embryonic stem cell-derived retinal pigment epithelial cells is affected by maturation stage.
Biomed Eng Online ;17(1)102, 2018
PMID

Vuorinen EM, Rajala NK, Ihalainen TO, Kallioniemi A
Depletion of nuclear import protein karyopherin alpha 7 (KPNA7) induces mitotic defects and deformation of nuclei in cancer cells.
BMC Cancer ;18(1)325, 2018
PMID

Ampuja M, Kallioniemi A
Transcription factors-Intricate players of the bone morphogenetic protein signaling pathway.
Genes Chromosomes Cancer ;57(1)3-11, 2018
PMID

Pirkko Kellokumpu-LehtinenRadiotherapy and Oncology

Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
J Clin Oncol ;37(7)559-569, 2019
PMID

Mannisto S, Vähämurto P, Pollari M, Clausen MR, Jyrkkiö S, Kellokumpu-Lehtinen PL, Kovanen P, Karjalainen-Lindsberg ML, d'Amore F, Leppä S
Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma.
Eur J Cancer ;2019
PMID

Wu X, Reinikainen P, Kapanen M, Vierikko T, Ryymin P, Kellokumpu-Lehtinen PL
Monitoring radiotherapy induced tissue changes in localized prostate cancer by multi-parametric magnetic resonance imaging (MP-MRI).
Diagn Interv Imaging ;2019
PMID

Skyttä T, Tuohinen S, Luukkaala T, Virtanen V, Raatikainen P, Kellokumpu-Lehtinen PL
.
Acta Oncol ;2019
PMID

Tiainen L, Hämäläinen M, Luukkaala T, Tanner M, Lahdenperä O, Vihinen P, Jukkola A, Karihtala P, Moilanen E, Kellokumpu-Lehtinen PL
Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent Long-Term Survival in Metastatic Breast Cancer.
Clin Breast Cancer ;2019
PMID

Leivonen SK, Pollari M, Brück O, Pellinen T, Autio M, Karjalainen-Lindsberg ML, Mannisto S, Kellokumpu-Lehtinen PL, Kallioniemi O, Mustjoki S, Leppä S
T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.
Haematologica ;104(2)338-346, 2019
PMID

Takala L, Bärlund M, Kellokumpu-Lehtinen PL
Effective Antiemetic Therapy Is Important With Adjuvant Anthracycline-based Chemotherapy in Breast Cancer.
Anticancer Res ;39(1)279-283, 2019
PMID


Wu X, Reinikainen P, Kapanen M, Vierikko T, Ryymin P, Kellokumpu-Lehtinen PL
Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage.
Contrast Media Mol Imaging ;2018
PMID

Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M, Nyandoto P, Villman KK, Halonen P, Granstam-Björneklett H, Lundgren L, Sailas L, Turpeenniemi-Hujanen T, Tanner M, Yachnin J, Ritchie D, Johansson O, Huttunen T, Neven P, Canney P, Harvey VJ, Kellokumpu-Lehtinen PL, Lindman H
Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.
JAMA Oncol ;4(9)1199-1206, 2018
PMID

Tuohinen SS, Keski-Pukkila K, Skyttä T, Huhtala H, Virtanen V, Kellokumpu-Lehtinen PL, Raatikainen P, Nikus K
Radiotherapy-induced Early ECG Changes and Their Comparison with Echocardiography in Patients with Early-stage Breast Cancer.
Anticancer Res ;38(4)2207-2215, 2018
PMID

Pollari M, Brück O, Pellinen T, Vähämurto P, Karjalainen-Lindsberg ML, Mannisto S, Kallioniemi O, Kellokumpu-Lehtinen PL, Mustjoki S, Leivonen SK, Leppä S
+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma.
Haematologica ;103(11)1908-1914, 2018
PMID

Aula H, Skyttä T, Tuohinen S, Luukkaala T, Hämäläinen M, Virtanen V, Raatikainen P, Moilanen E, Kellokumpu-Lehtinen PL
Decreases in TGF-β1 and PDGF levels are associated with echocardiographic changes during adjuvant radiotherapy for breast cancer.
Radiat Oncol ;13(1)201, 2018
PMID

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
Eur Urol ;73(2)178-211, 2018
PMID

Sperinde J, Huang W, Vehtari A, Chenna A, Kellokumpu-Lehtinen PL, Winslow J, Bono P, Lie YS, Petropoulos CJ, Weidler J, Joensuu H
p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial.
Clin Cancer Res ;24(13)3046-3052, 2018
PMID

Schmidt M, Weyer-Elberich V, Hengstler JG, Heimes AS, Almstedt K, Gerhold-Ay A, Lebrecht A, Battista MJ, Hasenburg A, Sahin U, Kalogeras KT, Kellokumpu-Lehtinen PL, Fountzilas G, Wirtz RM, Joensuu H
Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population.
Breast Cancer Res ;20(1)15, 2018
PMID

Hietanen T, Kapanen M, Kellokumpu-Lehtinen PL
Natural Killer Cell Viability After Hyperthermia Alone or Combined with Radiotherapy with or without Cytokines.
Anticancer Res ;38(2)655-663, 2018
PMID

Pajamäki N, Metso S, Hakala T, Ebeling T, Huhtala H, Ryödi E, Sand J, Jukkola-Vuorinen A, Kellokumpu-Lehtinen PL, Jaatinen P
Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer.
Clin Endocrinol (Oxf) ;88(2)303-310, 2018
PMID

Olli LohiHematology and oncology

Pölönen P, Mehtonen J, Lin J, Liuksiala T, Häyrynen S, Teppo S, Mäkinen A, Kumar A, Malani D, Pohjolainen V, Porkka K, Heckman CA, May P, Hautamäki V, Granberg KJ, Lohi O, Nykter M, Heinäniemi M
Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies.
Cancer Res ;79(10)2466-2479, 2019
PMID

Wolthers BO, Mogensen PR, Frandsen TL, Abrahamsson J, Behrendtz M, Heyman M, Lohi O, Norén-Nyström U, Ruud E, Schmiegelow K
Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia.
Pediatr Blood Cancer ;66(1)e27437, 2019
PMID


Nordfors K, Haapasalo J, Afyounian E, Tuominen J, Annala M, Häyrynen S, Karhu R, Helén P, Lohi O, Nykter M, Haapasalo H, Granberg KJ
ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma.
Cold Spring Harb Mol Case Stud ;2018
PMID

Norberg A, Rosén A, Raaschou-Jensen K, Kjeldsen L, Moilanen JS, Paulsson-Karlsson Y, Baliakas P, Lohi O, Ahmed A, Kittang AO, Larsson P, Roos G, Degerman S, Hultdin M
Novel variants in Nordic patients referred for genetic testing of telomere-related disorders.
Eur J Hum Genet ;26(6)858-867, 2018
PMID

de Bock CE, Demeyer S, Degryse S, Verbeke D, Sweron B, Gielen O, Vandepoel R, Vicente C, Vanden Bempt M, Dagklis A, Geerdens E, Bornschein S, Gijsbers R, Soulier J, Meijerink JP, Heinäniemi M, Teppo S, Bouvy-Liivrand M, Lohi O, Radaelli E, Cools J
HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.
Cancer Discov ;8(5)616-631, 2018
PMID

Nikkilä A, Raitanen J, Lohi O, Auvinen A
Radiation exposure from computerized tomography and risk of childhood leukemia: Finnish register-based case-control study of childhood leukemia (FRECCLE).
Haematologica ;103(11)1873-1880, 2018
PMID

Nikkilä A, Kendall G, Raitanen J, Spycher B, Lohi O, Auvinen A
Effects of incomplete residential histories on studies of environmental exposure with application to childhood leukaemia and background radiation.
Environ Res ;2018
PMID

Poukka M, Lund-Aho T, Raittinen P, Nikkilä A, Kivinen K, Lundán T, Porkka K, Lohi O
Acute Lymphoblastic Leukemia With INPP5D-ABL1 Fusion Responds to Imatinib Treatment.
J Pediatr Hematol Oncol ;2018
PMID

Nordfors K, Haapasalo J, Afyounian E, Tuominen J, Annala M, Häyrynen S, Karhu R, Helén P, Lohi O, Nykter M, Haapasalo H, Granberg KJ
ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma.
Cold Spring Harb Mol Case Stud ;2018
PMID

Johanna MäenpääGynaecological oncology

Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, Kehoe ST, Konishi I, Olawaiye AB, Prat J, Sankaranarayanan R, Brierley J, Mutch D, Querleu D, Cibula D, Quinn M, Botha H, Sigurd L, Rice L, Ryu HS, Ngan H, Mäenpää J, Andrijono A, Purwoto G, Maheshwari A, Bafna UD, Plante M, Natarajan J
Revised FIGO staging for carcinoma of the cervix uteri.
Int J Gynaecol Obstet ;145(1)129-135, 2019
PMID

Aalto AP, Huhtala H, Mäenpää J, Staff S
Combination of Treatments With or Without Surgery in Localized Provoked Vulvodynia: Outcomes After Three Years of Follow-Up.
Biores Open Access ;8(1)25-31, 2019
PMID

Veijalainen O, Kares S, Kujala P, Vuento R, Osuala V, Tirkkonen M, Luukkaala T, Kholová I, Mäenpää J
Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
Cytopathology ;30(2)150-156, 2019
PMID


Veijalainen O, Kares S, Kujala P, Vuento R, Osuala V, Tirkkonen M, Luukkaala T, Kholová I, Mäenpää J
Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
Cytopathology ;2018
PMID

Antila-Långsjö R, Mäenpää JU, Huhtala H, Tomás E, Staff S
Comparison of transvaginal ultrasound and saline contrast sonohysterography in evaluation of cesarean scar defect: a prospective cohort study.
Acta Obstet Gynecol Scand ;97(9)1130-1136, 2018
PMID

Niemi RJ, Roine AN, Eräviita E, Kumpulainen PS, Mäenpää JU, Oksala N
FAIMS analysis of urine gaseous headspace is capable of differentiating ovarian cancer.
Gynecol Oncol ;151(3)519-524, 2018
PMID

Antila-Långsjö RM, Mäenpää JU, Huhtala HS, Tomás EI, Staff SM
Cesarean scar defect: a prospective study on risk factors.
Am J Obstet Gynecol ;219(5)458.e1-458.e8, 2018
PMID

Niemi RJ, Braicu EI, Kulbe H, Koistinen KM, Sehouli J, Puistola U, Mäenpää JU, Hilvo M
Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism.
Br J Cancer ;119(7)847-854, 2018
PMID

Mäenpää MM, Nieminen K, Tomás EI, Luukkaala TH, Mäenpää JU
Robotic-Assisted Infrarenal Para-aortic Lymphadenectomy in Gynecological Cancers: Technique and Surgical Outcomes.
Int J Gynecol Cancer ;28(5)951-958, 2018
PMID

Daniela UngureanuCancer Signalling

Karvonen H, Perttilä R, Niininen W, Hautanen V, Barker H, Murumägi A, Heckman CA, Ungureanu D
Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
Oncogene ;38(17)3288-3300, 2019
PMID


Karvonen H, Perttilä R, Niininen W, Barker H, Ungureanu D
Targeting Wnt signaling pseudokinases in hematological cancers.
Eur J Haematol ;101(4)457-465, 2018
PMID

Karvonen H, Summala K, Niininen W, Barker HR, Ungureanu D
Interaction between ROR1 and MuSK activation complex in myogenic cells.
FEBS Lett ;592(3)434-445, 2018
PMID

Teuvo Tammela (previous Tapio Visakorpi) – Molecular Biology of Prostate Cancer


Latonen L, Afyounian E, Jylhä A, Nättinen J, Aapola U, Annala M, Kivinummi KK, Tammela TTL, Beuerman RW, Uusitalo H, Nykter M, Visakorpi T
Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression.
Nat Commun ;9(1)1176, 2018
PMID

Schiewer MJ, Mandigo AC, Gordon N, Huang F, Gaur S, de Leeuw R, Zhao SG, Evans J, Han S, Parsons T, Birbe R, McCue P, McNair C, Chand SN, Cendon-Florez Y, Gallagher P, McCann JJ, Poudel Neupane N, Shafi AA, Dylgjeri E, Brand LJ, Visakorpi T, Raj GV, Lallas CD, Trabulsi EJ, Gomella LG, Dicker AP, Kelly WK, Leiby BE, Knudsen B, Feng FY, Knudsen KE
PARP-1 regulates DNA repair factor availability.
EMBO Mol Med ;2018
PMID

Kartasalo K, Latonen L, Vihinen J, Visakorpi T, Nykter M, Ruusuvuori P
Comparative analysis of tissue reconstruction algorithms for 3D histology.
Bioinformatics ;34(17)3013-3021, 2018
PMID

Kallio HML, Hieta R, Latonen L, Brofeldt A, Annala M, Kivinummi K, Tammela TL, Nykter M, Isaacs WB, Lilja HG, Bova GS, Visakorpi T
Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.
Br J Cancer ;119(3)347-356, 2018
PMID

Latonen L, Nykter M, Visakorpi T
Proteomics of prostate cancer - revealing how cancer cells master their messy genomes.
Oncoscience ;5(7-8)216-217, 2018
PMID

Sainio M, Visakorpi T, Tolonen T, Ilvesaro J, Bova GS
Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Pathol Res Pract ;214(6)848-856, 2018
PMID

Claessens F, Visakorpi T
Endocrinology of prostate cancer.
Mol Cell Endocrinol ;462(Pt A)1-2, 2018
PMID

McNair C, Xu K, Mandigo AC, Benelli M, Leiby B, Rodrigues D, Lindberg J, Gronberg H, Crespo M, De Laere B, Dirix L, Visakorpi T, Li F, Feng FY, de Bono J, Demichelis F, Rubin MA, Brown M, Knudsen KE
Differential impact of RB status on E2F1 reprogramming in human cancer.
J Clin Invest ;128(1)341-358, 2018
PMID

Högnäs G, Kivinummi K, Kallio HML, Hieta R, Ruusuvuori P, Koskenalho A, Kesseli J, Tammela TLJ, Riikonen J, Ilvesaro J, Kares S, Hirvikoski PP, Laurila M, Mirtti T, Nykter M, Kujala PM, Visakorpi T, Tolonen T, Bova GS
Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues.
Am J Surg Pathol ;42(1)103-115, 2018
PMID